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Abstract
We reported the case of a 70-year-old woman with mod-
erate renal failure due to anti-neutrophil cytoplasmic
antibody-related glomerulonephritis who developed symp-
tomatic water intoxication (serum Na: 108 mEq/L) fol-
lowing treatment with oral low-dose cyclophosphamide
(CY) (50mg/day). Estimated glomerular filtration rate was
29.5 mL/min/1.73 m2. She had drunk >2Lo ff l u i di n1 2h
prior to the development of cerebral oedema. This rare case
suggests that oral low-dose CY could be an occult cause of
water intoxication in patients with chronic kidney disease
taking large fluid volumes.
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Introduction
Cyclophosphamide (CY) is an alkylating drug often used
forrheumatologicdiseasessuchasanti-neutrophilcytoplas-
mic antibody (ANCA)-related glomerulonephritis (GN).
Water intoxication following intravenous low-dose CY is
reported rarely to cause life-threatening water intoxication
[1–4]. Herein, we report the case of an elderly woman
with ANCA-related GN who developed symptomatic wa-
ter intoxication following low-dose oral CY treatment for
1 month.
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Case report
A 70-year-old woman with ANCA-related GN was emer-
gently readmitted to our hospital due to the development
of nausea, vomiting, confusion and mental disorientation
concomitantly on 9 January 2006. She had previously been
admitted to our hospital due to anaemia and a rapid in-
crement of serum creatinine from 0.69 to 3.08 mg/dL
in the previous 3 months on 28 October 2005. After
admission, serum creatinine had maximally increased to
5.22 mg/dL. Due to the presence of 123 EU of serum
myeloperoxidase (MPO)—ANCA titre and crescentic GN
in the kidney biopsy—we diagnosed her as having ANCA-
related GN. After twice methylprednisolone pulse therapy
(500 mg/day), we had started 30 mg/day of oral pred-
nisolone (PSL) on 7 November and subsequently added
oral CY [50 mg/day, 1.4 mg/kg body weight (BW)/day]
since 6 December. She had been discharged from our
hospital on 20 December, with 20 mg/day of PSL and
50 mg/day of CP. At discharge, her serum creatinine had
decreased to 1.98 mg/dL with normal serum sodium (Na)
(138 mEq/L). On 6 January 2006, she first visited our out-
patient clinic. After discharge, she had been taking fluids to
maintain urinary flow to avoid haemorrhagic cystitis. Her
serum Na had decreased to 130 mEq/L without any clinical
symptoms.
At readmission, blood pressure was elevated to 169/
87 mmHg, but there was no pitting oedema in either leg.
Her body weight remained at 37 kg. Serum NA decreased
to 108 mEq/L with plasma osmolality of 233 mOsm/kg
H2O, while urinary Na excretion was 55 mEq/L with uri-
nary osmolality of 246 mOsm/kg H2O. Laboratory exam-
ination revealed as follows: haemoglobin 9.9 g/dL, serum
creatinine 1.31 mg/dL, blood urea nitrogen 25.9 mg/dL,
potassium 4.1 mEq/L, chloride 79 mEq/L, plasma glucose
116 mg/dL and bicarbonate 24.9 mmol/L. Her serum al-
bumin decreased to 3.2 g/dL, with 31 mL/min of creati-
nineclearance(Ccr)and29.5mL/min/1.73m2 ofestimated
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Fig. 1. Cerebral oedema due to water intoxication. Plain brain CT scan revealed marked swelling of the sulcus at the frontal lobe and narrowing
of cerebral ventricles at re-admission. Following the discontinuation of CY treatment and fluid restriction, hyponatraemia was promptly restored by
72 h without any disorientation. CT scan also revealed no cerebral oedema at hospital Day 10. Abbreviations are CT: computed tomography and CY:
cyclophosphamide.
glomerular filtration rate (eGFR) calculated by the Modi-
fication of Diet in Renal Disease (MDRD) Study equation
[5]. Plain brain computed tomography (CT) scan revealed
brain oedema such as swelling of the sulcus at the frontal
lobe and ventricular narrowing (Figure 1A).
Endocrine hormone examination at early morning on
10 January disclosed as follows: plasma ACTH 155 pg/mL
(normal, 7.4–55.7), cortisol 17.7 µg/dL (normal, 5.3–11.0)
and aldosterone 311 pg/mL (normal, 29.9–159). Thyroid
function was within normal range. Plasma renin activ-
ity was suppressed to 0.2 ng/mL/h (normal, 0.3–2.9), and
plasma human atrial natriuretic peptide (ANP) was ele-
vated to 80 pg/mL (normal, ≤40), a compatible finding
with overhydration. Plasma antidiuretic hormone (ADH)
was 2.7 pg/mL (normal, 0.3–3.5), despite the presence of
hyponatraemia (Na: 119 mEq/L).
We diagnosed the patient as having water intoxication in
view of hyponatraemia with an inappropriately high urine
osmolarity. We first suspected the CY-induced water intox-
ication combined with massive hydration. After stopping
oral CY, the fluid intake was restricted by 1 L/day of 0.9%
saline solution. By 72 h after readmission, she was fully
oriented with normal electrolyte concentrations. In retro-
spective, she reported that she had drunk >2 L of fluid
in the 12 h prior to the readmission. Plain brain CT scan
on day 10 showed the improvement of sulcus swelling and
ventricular narrowing (Figure 1B).
One month after the cessation of CY, we conducted a
water-loading test (20 mL/kg body weight) by infusing
5% glucose solution for 30 min (Scr: 1.54 mg/dL, eGFR:
26.8 ml/min/1.73 m2). By 4 h, a total of 85% of the loaded
volume was excreted into the urine, and urinary osmolality
decreased from 369 to 150 mOsm/kg H2O. Plasma ADH
also decreased to 1.2 pg/mL with 130 mEq/L of serum
Na at 2 h after the loading. Until April 2008, she has not
experienced any episode of hyponatraemia.
Discussion
It was initially thought that water intoxication developed
in doses >50 mg/kg BW of CY [6]. However, this is not
true, since some observations have shown that low-dose
CY also, but rarely, causes water intoxication [1–4]. To the
best of our knowledge, there were five cases that devel-
oped symptomatic water intoxication following low-dose
CY (<15 mg/kg BW) (Table 1). In all of the cases, the
drug was given intravenously. In this case, we first experi-
enced severe hyponatraemia in an elderly women with oral
administration of low-dose CY (daily dose: 1.4 mg/kg) for
1 month.
That CY was responsible for hyponatraemia in this
patient is supported by some observations. First, her
hyponatraemia had first become evident 1 month after oral
CY treatment. By stopping CY and water restriction, her
hyponatraemiasoondissolvedandhavenotoccurredagain.
Second, the water-loading test at 1 month after CY cessa-
tion revealed normal excretion of free water, indicating no
prior impairment of water excreting ability. Third, no other
cause of hyponatraemia was apparent. Nausea is a potent
stimulus to release ADH, but her plasma ADH remained
within normal range. In addition, nausea soon dissolved
concomitantlywiththecorrectionofhyponatremiabywater
restriction.Otherstudyalsoshowedthatnoriseofplasmais288 Kato et al.
Table 1. Patient characteristics of water intoxication following low-dose CY
Age (years) Sex Original diseases CY dosage Scr (mg/dL) Serum Na (mEq/L) Fluid intake Ref.
68 M MM 500 mg, iv 0.96 108 3 L/day [1]
59 F SLE 10 mg/kg, iv 0.63 116 2.4 L/day [2]
57 F Sj¨ ogren 780 mg, iv 0.6 117 >0.95 L/6 h [3]
48 F SLE 750 mg, iv (12.5 mg/kg) 0.72 119 3 L/day [4]
53 F SLE 500 mg, iv ND 119 3 L/2 h [4]
70 F ANCA-related GN 50 mg (1.4 mg/kg) 1.31 108 >2 L/12 h This case
CY: cyclophosphamide, MM: multiple myeloma, SLE: systemic lupus erythematosus, ANCA-related GN: anti-neutrophil cytoplasmic antibody-related
glomerulonephritis, Scr: serum creatinine, Na: sodium and ND: not determined.
observed during moderate-dose CY infusion [7]. However,
the water-loading test when recovered from hyponatraemia
decreased plasma ADH to 1.2 pg/mL, indicating that the
level of plasma ADH (2.7 pg/mL) at readmission was
relatively high in association with CY therapy. Since a
case has been reporte of an 8-year-old girl with established
diabetes inspipidus with hyponatraemia caused by CY
infusion despite an inability to secrete ADH [8], one or
more CY metabolites may directly alter water permeability
in the kidney.
One certain factor that possibly may contribute to water
intoxication was excess fluid intake in this case. Previously
reportedcasesthatdevelopedseverehyponatraemiabylow-
dose CP also received oral hydration >2–3 L of fluid a day.
Other causative factors responsible for water intoxication
were the presence of renal failure and hypoalbuminaemia.
Moderate renal failure (Ccr: 25–50 mL/min) prolongs the
half-life of CY (50–100 mg/m2 as a 1-h infusion) from
4.8 to 6.4 h [9]. Since hyponatraemia was already evident
3 days before re-admission, accumulated CY metabolites
by continuous oral regimen may gradually progress to hy-
ponatraemia.
In summary, we experienced the case of an elderly
woman with impaired renal function who developed symp-
tomatic hyponatraemia following oral CY administration
for 1 month. In this case, the patient had been taking over
2 L of fluid per day according to the general advice to avoid
the risk of cystitis, which may contribute to water intoxica-
tion.Thus,nephrologistsshouldbeawarethatorallow-dose
CY could be an occult cause of water intoxication in renal
failurepatientsandshouldadvisethepatienttotakesodium
chloride when using oral hydration.
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